Page 42 - 《中国药房》2025年16期
P. 42

利舒康胶囊调节HIF-1α/NF-κB信号通路对大鼠低氧性肺动脉高

          压的影响
                        Δ


                                   1
                                           2 #
                           1
                 1*
          李龙昱 ,徐富菊 ,王 欣 ,张松达 (1.青海省人民医院药学部,西宁 810000;2.青海省第四人民医院药剂
          科,西宁 810000)
          中图分类号  R965      文献标志码  A      文章编号  1001-0408(2025)16-1988-05
          DOI  10.6039/j.issn.1001-0408.2025.16.06

          摘   要  目的  探究利舒康胶囊调节低氧诱导因子1α(HIF-1α)/核因子κB(NF-κB)信号通路对大鼠低氧性肺动脉高压(HPAH)的
          影响。方法  60只大鼠随机分为对照组、模型组、阳性对照组(西地那非30 mg/kg)和利舒康低、中、高剂量组(利舒康胶囊6、12、18
          g/kg),每组10只。除对照组外,其余各组大鼠采用间歇性低氧法(模拟5 000 m海拔)建立HPAH模型;建模同时每日灌胃相应药
          物或生理盐水,连续28 d。末次给药24 h内,检测大鼠平均肺动脉压(MPAP)和右心室肥厚指数(RVHI),观察肺组织病理情况,检
          测肺组织中α平滑肌肌动蛋白(α-SMA)表达和HIF-1α、NF-κB mRNA表达,以及HIF-1α、NF-κB p65蛋白表达情况。结果  与模
          型组比较,利舒康中、高剂量组和阳性对照组大鼠的MPAP、RVHI均显著降低(P<0.05);肺组织中α-SMA表达和HIF-1α、NF-κB
          mRNA 表达,以及 HIF-1α 和 NF-κB p65 蛋白表达均显著下调(P<0.05);肺血管重塑均不同程度改善。结论  利舒康胶囊对大鼠
          HPAH具有改善作用,其机制可能与抑制HIF-1α/NF-κB信号通路有关。
          关键词  利舒康胶囊;低氧性肺动脉高压;肺血管重塑;低氧诱导因子1α;核因子κB

          Effects of Lishukang capsules on hypoxic pulmonary artery hypertension in rats by modulating the HIF--1α/
          NF--κB signaling pathway
                                           1
          LI Longyu ,XU Fuju ,WANG Xin ,ZHANG Songda(1.  Dept.  of  Pharmacy,  Qinghai  Provincial  People’s
                    1
                                                           2
                              1
          Hospital,  Xining  810000,  China;2.  Dept.  of  Pharmacy,  Fourth  People’s  Hospital  of  Qinghai  Province,  Xining
          810000, China)
          ABSTRACT    OBJECTIVE To explore the effects of Lishukang capsules on hypoxic pulmonary artery hypertension (HPAH) rats
          by  regulating  the  HIF-1α/NF- κB  signaling  pathway.  METHODS  Sixty  rats  were  randomly  divided  into  control  group,  model
          group, positive control group (sildenafil, 30 mg/kg), Lishukang low-, medium- and high-dose groups (Lishukang capsules 6, 12,
          18     g/kg), with 10 rats in each group. Except for control group, the HPAH model was induced by intermittent hypoxia method
         (simulating  an  altitude  of  5  000  m)  in  other  groups;  at  the  same  time,  they  were  given  relevant  medicine  or  normal  saline
          intragastrically,  for  consecutive  28  days. Within  24  hours  of  the  last  administration,  the  mean  pulmonary  artery  pressure (MPAP)
          and  right  ventricule  hypertrophy  index (RVHI)  of  rats  were  detected;  pathological  morphology  of  lung  tissue  was  observed,  and
          the  expression  of  α-smooth  muscle  actin (α-SMA),  mRNA  expressions  of  HIF-1α  and  NF-κB  as  well  as  protein  expressions  of
          HIF-1α  and  NF-κB  p65  in  lung  tissue  were  determined.  RESULTS  Compared  with  model  group,  MPAP  and  RVHI  in  Lishukang
          medium-  and  high-dose  groups  and  positive  control  group  were  all  decreased  significantly (P<0.05);  the  expression  of  α-SMA,
          mRNA  expressions  of  HIF-1α  and  NF-κB,  and  protein  expressions  of  HIF-1α  and  NF-κB  p65  in  lung  tissue  were  all  decreased
          significantly (P<0.05);  additionally,  pulmonary  vascular  remodeling  was  improved  to  varying  degrees.  CONCLUSIONS
          Lishukang  capsules  may  protect  HPAH  rats,  the  mechanism  of  which  may  be  associated  with  inhibiting  the  HIF-1α/NF- κB
          signaling pathway.
          KEYWORDS     Lishukang capsules; hypoxic pulmonary artery hypertension; pulmonary vascular remodeling; HIF-1α; NF-κB


              低氧性肺动脉高压(hypoxic pulmonary artery hyper‐        肺动脉血流阻力增加为主要特征的肺血管疾病,好发于
          tension,HPAH)是一种在低氧环境下以肺动脉壁增厚和                      高海拔地区的人群 。HPAH 发生时,肺血管持续收缩
                                                                              [1]
              Δ 基金项目 青海省科技创新普及专题项目(No.2024-SF-004)            导致肺动脉结构重塑,使右心压力负荷增加,最终进展
             * 第一作者 副 主 任 药 师 。 研 究 方 向 :医 院 药 学 。 E-mail:    为右心衰竭,严重威胁人类健康 。目前,临床尚缺乏
                                                                                          [2]
          13897488618@139.com
                                                              HPAH治疗的有效药物,因此,开发HPAH药物具有重要
              #  通信作者 副 主 任 药 师 。 研 究 方 向 :医 院 药 学 。 E-mail:
          zhsd020606@163.com                                  的临床意义。


          · 1988 ·    China Pharmacy  2025 Vol. 36  No. 16                            中国药房  2025年第36卷第16期
   37   38   39   40   41   42   43   44   45   46   47